A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
This study is testing a new experimental drug, called BMS-986523, to see if it is safe and effective at fighting advanced solid cancers. Researchers want to learn if this new drug works better on its own or when combined with other common cancer treatments.
You may be eligible if you have an advanced solid tumor that has a specific 'KRAS' genetic mutation and has not responded well to previous treatments. Participants must also have high levels of a protein called PD-L1 in their tumor cells.
You will receive the experimental drug, either alone or alongside other chemotherapy or immunotherapy treatments, while doctors closely monitor your health. Regular check-ups will be required to track how your body responds to the treatment and to ensure your safety.
The study is currently recruiting patients at medical centers in Baltimore, Maryland; San Antonio, Texas; and West Valley City, Utah.
- 1This is an early-stage study designed to check both safety and how well the drug works.
- 2The study focuses on tumors with specific genetic markers, including the KRAS mutation.
- 3Participation involves strict health criteria, such as having no active cancer in the brain or spine.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.